Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007341
Chunk: 17

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 17
---
,137,075 Ordinary Shares upon the exercise of pre-funded warrants, Series A Warrants and Series B
Warrants issued in the February Private Placement.

On May 26, 2023, we completed
the closing of a registered direct offering with institutional investors of (1) 166,017,700 Ordinary Shares represented by 16,601
Depositary Shares, issuable upon the exercise of the Series C warrants, or Series C Warrants, at an exercise price of $400.00 per warrant,
(2) 110,675,600 Ordinary Shares represented by 11,059 Depositary Shares issuable upon the exercise of the Series D warrants, or Series
D Warrants, at an exercise price of $400.00 per warrant and, (3) 4,426,800 Ordinary Shares represented by 442 Depositary Shares issuable
upon the exercise of warrants issued to the placement agent in the offering at an exercise price of $375.00 per warrant, or May 2023 Placement
Agent Warrants.

On June 14, 2023, we held
our June AGM, and our shareholders passed resolutions, among other procedural items, to approve the allotment of, and disapplication of
pre-emption rights in respect of, up to 7.0 billion Ordinary Shares. On June 14, 2023, we also held a June GM, and our shareholders passed
resolutions to, among other things, (i) re-designate our deferred shares into A Deferred Shares, and (ii) subdivide our Ordinary Shares
of £0.02 nominal value each into one Ordinary Share of £0.001 nominal value and 19 B Deferred Shares of £0.001 nominal
value each.

On June 20, 2023, we issued
the Series C Warrants, Series D Warrants and May 2023 Placement Agent Warrants after receiving required shareholder approval of the allotment
of, and disapplication of pre-emption rights with respect to the Ordinary Shares to be issued under the warrants at our June GM.

Between June 20, 2023, and
December 31, 2024, we have issued 166,017,700 ordinary shares upon the exercise of Series C Warrants issued in the May 2023 registered
direct offering, or May 2023 Registered Direct Offering.

On July 5, 2023, we effected
a ratio change to the Depositary Shares, pursuant to which the ratio